+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)



Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2)



International Journal of Radiation Oncology, Biology, Physics 97(3): 536-545



To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer. We enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade ≥3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life. From October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0 months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade ≥3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade ≥3 neutropenia (8.6% vs 27.1%; 2-sided χ2P=.035) and nonsignificantly lower incidence of grade ≥3 leukopenia (25.7% vs 41.7%; P=.13) and any grade ≥3 hematologic toxicity (31.4% vs 43.8%; P=.25). IMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059454120

Download citation: RISBibTeXText

PMID: 28126303

DOI: 10.1016/j.ijrobp.2016.11.027


Related references

Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer. International Journal of Gynecological Cancer 22(8): 1427-1434, 2013

Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics 79(4): 1081-1088, 2011

A dosimetric analysis of intensity-modulated radiation therapy with bone marrow sparing for cervical cancer. Anticancer Research 34(9): 5091-5098, 2014

Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer. RadioTherapy and Oncology 123(2): 325-330, 2018

Bone marrow-sparing intensity modulated radiation therapy versus conventional techniques in cervical cancer patients. International Journal of Radiation Oncology Biology Physics 69(3): S401, 2007

Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head and Neck 38(Suppl. 1): E566-E570, 2018

Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer. Journal of Applied Clinical Medical Physics 11(4): 3255, 2011

Dosimetric comparison between bone marrow sparing intensity-modulated radiation therapy and conventional techniques in the treatment of cervical cancer: a retrospective study. Gulf Journal of Oncology 1(13): 30-41, 2016

Bone marrow-sparing intensity-modulated radiation therapy for Stage I seminoma. Acta Oncologica 50(4): 555-562, 2011

Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. International Journal of Radiation Oncology, Biology, Physics 100(3): 730-737, 2017

Prospective study of functional bone marrow-sparing intensity modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. International Journal of Radiation Oncology, Biology, Physics 85(2): 406-414, 2013

Intensity Modulated Radiation Therapy or 3D Conformal Radiation Therapy Combined with Brachytherapy and Concurrent Chemoradiotherapy in Advanced Cervical Cancer: A Retrospective Multicenter Study. International Journal of Radiation Oncology*Biology*Physics 102(3): e638-e639, 2018

Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin. International Journal of Gynecological Cancer 23(1): 119-125, 2013

Comparison of intensity modulated radiation therapy (IMRT) with conventional radiotherapy (CRT) for cervical cancer with concurrent cisplatin (CDDP). Journal of Clinical Oncology 26(15_Suppl): 5562-5562, 2016

A randomized controlled trial of intensity-modulated radiation therapy plus docetaxel and cisplatin versus simple intensity-modulated radiation therapy in II-III stage esophageal carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi 16(9): 842-845, 2014